Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily caused by resisting leukemic stem cells (LSCs), which preven...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2020-10, Vol.34 (10), p.2635-2647
Hauptverfasser:	Parting, Oliver, Langer, Samantha, Kuepper, Maja Kim, Wessling, Caroline, Li, Shaoguang, Braunschweig, Till, Chatain, Nicolas, Maié, Tiago, Costa, Ivan G., Crysandt, Martina, Huber, Michael, Brümmendorf, Tim H., Koschmieder, Steffen, Schemionek, Mirle
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/100 13/31 13/95 631/532/71 631/67/1990 64/60 Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Animals Antineoplastic Agents - pharmacology Apoptosis BCR-ABL protein Bruton's tyrosine kinase Cancer Research CD34 antigen Cell proliferation Chronic myeloid leukemia Critical Care Medicine Depletion Enzyme inhibitors Fc receptors Fusion protein Fusion Proteins, bcr-abl - antagonists & inhibitors Hematology Humans Immunoreceptor tyrosine-based inhibition motif Intensive Internal Medicine Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Medicine Medicine & Public Health Mice Mice, Inbred C57BL Myeloid leukemia Neoplastic Stem Cells - metabolism Oncology Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Receptors, IgG - antagonists & inhibitors Receptors, IgG - genetics Remission Signal Transduction - drug effects Signaling Stem cell transplantation Stem cells Targeted cancer therapy Therapy Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!